As an example, a phase 1/2 trial is testing Tazemetostat, an EZH2 inhibitor, in combination with the immune-checkpoint inhibitor pembrolizumab in patients with advanced urothelial carcinoma (https://clinicaltrials.gov: NCT03854474, accessed on 8 January 2023). This evidence concerns the gene EZH2 and urothelial carcinoma.